CIP News
GAPVAC
GAPVAC consortium reports first-in-human trial of a novel actively personalized therapeutic vaccine for brain cancer in Nature. https://www.nature.com/articles/s41586-018-0810-y
MDSCs Harmonization - Second phase
Results of the phase I proficiency panel have been published (S. Mandruzzato, PMID: 26728481).
Testing phase II (in silico) is completed and central analysis is ongoing.
Contact: susanna.mandruzzato[at]unipd.it
Proficiency panel collaboration
The proficiency panel programs established by CIP and CIC have reached a high degree of harmonization for two immune monitoring methods, the HLA-multimer staining and Interferon-gamma ELISPOT. Starting in Fall 2013, the company Immudex has taken on the organization of large-scale proficiency panels for these two assays.
For general information about the Immudex proficiency panels as well as upcoming panels, please go to the Immudex website.
T cell reference samples
Reference samples containing a controlled number of antigen-specific T cells that can be used for controlling assay performance overtime are urgently needed. In collaboration with the University Medical Clinic in Mainz and TRON, CIP has developed a RNA-based scalable technology which allows the generation of TCR-engineered reference samples (TERS) of selected specificities (Bidmon et al. doi: 10.4049). TERS can be used for controlling the performance of HLA-multimer, Elispot and ICS assays over time. TERS can be easily produced in-house using a kit-based approach. Since November 2016, TERS-kits have been proposed by the company jpt.